See more : SEL Manufacturing Company Limited (SELMC.NS) Income Statement Analysis – Financial Results
Complete financial analysis of CERo Therapeutics Holdings, Inc. (CEROW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CERo Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Rana Sugars Limited (RANASUG.NS) Income Statement Analysis – Financial Results
- Streamline Health Solutions, Inc. (STRM) Income Statement Analysis – Financial Results
- eEnergy Group Plc (EAAS.L) Income Statement Analysis – Financial Results
- RemeGen Co., Ltd. (9995.HK) Income Statement Analysis – Financial Results
- Howard Bancorp, Inc. (HBMD) Income Statement Analysis – Financial Results
CERo Therapeutics Holdings, Inc. (CEROW)
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 9.85M | 9.14M |
| General & Administrative | 2.89K | 2.13M | 2.48M |
| Selling & Marketing | 2.89M | 715.76K | -2.23M |
| SG&A | 2.89M | 2.84M | 251.71K |
| Other Expenses | 40.05K | -64.05K | -80.32K |
| Operating Expenses | 2.93M | 2.91M | 332.03K |
| Cost & Expenses | 2.93M | 2.91M | 332.03K |
| Interest Income | 491.57K | 142.12K | 986.71K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93K | 1.07M | 735.47K |
| EBITDA | -2.44M | -68.58K | -332.03K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.93M | -2.91M | -332.03K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 491.57K | 2.84M | 99.08K |
| Income Before Tax | -2.44M | -68.58K | -332.42K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 94.82K | 599.16K | -16.87K |
| Net Income | -2.54K | -667.74K | -315.55K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -0.10 | -0.01 |
| EPS Diluted | -0.39 | -0.10 | -0.01 |
| Weighted Avg Shares Out | 6.53M | 6.77M | 22.98M |
| Weighted Avg Shares Out (Dil) | 6.53M | 6.77M | 22.98M |
Source: https://incomestatements.info
Category: Stock Reports